Dr. Lal Pathlabs (LALPATHLAB) Share Price Falls 2.51% Today
- September 1, 2026
- Posted by: Harsh Piplani
- Category: News
Dr. Lal Pathlabs Share Price fell to Rs 1,891.25 on 01 September 2026, down 2.51% for the day, taking the company’s market capitalisation to Rs 32,406.57 crore. The Large Cap healthcare stock opened at Rs 1,923.45 and moved to an intraday low of Rs 1,876 before recovering part of the decline.
Today’s move has brought the stock into focus because the supplied data confirms a same-day decline from the previous close of Rs 1,939.95, with turnover at Rs 0.30 crore. The dataset establishes the price event, but it does not establish a company-specific reason for why the stock is falling today. That makes the discussion more about verified price action, valuation and sector positioning than about speculation.
For investors tracking Dr. Lal Pathlabs Share Price, the immediate questions are clear: how weak was the intraday move, what do the available indicators suggest, how demanding is the valuation, and how does the company compare with peers in Hospital & Healthcare Services. This analysis addresses those points using only the supplied numbers.
Dr. Lal Pathlabs (LALPATHLAB) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,891.25 |
| Previous Close | Rs 1,939.95 |
| Today's Move | -Rs 48.70 (-2.51%) |
| Open | Rs 1,923.45 |
| High | Rs 1,934.8 |
| Low | Rs 1,876 |
| Turnover | Rs 0.3 crore |
| Market Capitalisation | Rs 32,406.57 crore |
| Market Cap Category | Large Cap |
The stock was down Rs 48.70 from the previous close of Rs 1,939.95. It opened at Rs 1,923.45, touched an intraday high of Rs 1,934.80 and then fell to Rs 1,876. This range shows that pressure emerged early and pushed the stock well below the prior close during the session.
Even so, the current price remained above the day’s low, indicating that some of the intraday weakness was pared back. Turnover stood at Rs 0.30 crore. Since no verified catalyst is available in the supplied data, the most defensible reading is that today’s move is a clear price decline without an established headline trigger.
From a technical context, the stock is also trading close to an important medium-term reference point. The 50-day moving average is Rs 1,894.01, almost in line with the current price of Rs 1,891.25, while the 200-day moving average is much lower at Rs 1,586.05. That means the stock is slightly below its 50-DMA but still comfortably above its 200-DMA. The RSI is 55.44, which does not suggest an extreme reading on the supplied numbers.
Dr. Lal Pathlabs (LALPATHLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 32,406.57 crore |
| P/E Ratio | 60.09x |
| P/B Ratio | 12.46x |
| ROE | 22.37% |
| ROCE | 29.56% |
| EPS | Rs 32.29 |
| Book Value Per Share | Rs 155.67 |
| Dividend Yield | 1.06% |
The company remains a profitable large-cap healthcare business, but it trades at premium valuation multiples. Market capitalisation stands at Rs 32,406.57 crore, P/E at 60.09 and P/B at 12.46. EPS is Rs 32.29, book value per share is Rs 155.67 and dividend yield is 1.06%.
Profitability is a key support point in the numbers. ROE is 22.37% and ROCE is 29.56%, both of which indicate strong capital efficiency on the supplied data. In simple terms, the company is generating relatively strong returns on shareholder equity and capital employed, which helps explain why investors assign it a higher multiple than many industry participants.
At the same time, premium valuation can leave a stock more sensitive to shifts in sentiment. That does not explain today’s decline on its own, but it does help frame why even a moderate price move can attract attention. The fundamental picture, therefore, is not one of weak returns; it is one of strong profitability paired with relatively demanding valuation ratios.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Hospital & Healthcare Services |
| Benchmark Scope | same industry |
| Company P/E Ratio | 60.09x |
| Benchmark Median P/E | 47.88x |
| Benchmark Average P/E | 103.86x |
| Benchmark P/E Range | 7.74x to 1,515.36x |
| Company P/B Ratio | 12.46x |
| Benchmark Median P/B | 4.17x |
| Benchmark Average P/B | 4.72x |
| Company ROE | 22.37% |
| Benchmark Median ROE | 12.82% |
| Benchmark Average ROE | 13.8% |
| Company ROCE | 29.56% |
| Benchmark Median ROCE | 15.7% |
| Benchmark Average ROCE | 3.09% |
| Company Market Capitalisation | Rs 32,406.57 crore |
| Benchmark Median Market Cap | Rs 742.29 crore |
| Benchmark Average Market Cap | Rs 12,193.75 crore |
The same-industry benchmark covers 62 companies in Hospital & Healthcare Services. Within that set, the company’s P/E of 60.09 is above the median of 47.88 but below the average of 103.86 across 55 companies with available P/E data. The industry range is wide, from 7.74 to 1,515.36, which shows how dispersed valuations are in this segment.
On price-to-book, the company stands at 12.46 versus an industry median of 4.17 and average of 4.72, placing it at a clear premium. Profitability, however, looks stronger than benchmark norms. ROE of 22.37% is well above the median of 12.82% and average of 13.8%, while ROCE of 29.56% is higher than the median of 15.7% and the average of 3.09%.
Scale also matters in sector interpretation. At Rs 32,406.57 crore, the company is far larger than the industry median market cap of Rs 742.29 crore and above the average of Rs 12,193.75 crore. So the sector picture is fairly balanced: the stock trades at a premium to typical peers on valuation, but the business also posts stronger returns than the broader industry sample.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | APOLLOHOSP | 1,27,187.59 | 60.97 | 13.15 | 23.54 | 21.73 |
| MANIPAL HEALTH ENTERPRI L | MANIPALHOS | 1,01,527.39 | 112.4 | 5.5 | 12.95 | 13.93 |
| Max Healthcare Institute | MAXHEALTH | 98,597.77 | 68.07 | 9.08 | 14.53 | 14.97 |
| Fortis Healthcare | FORTIS | 70,211.11 | 65.42 | 6.75 | 11.32 | 14.07 |
| Aster DM Healthcare | ASTERDM | 64,952.67 | 206.73 | 13.26 | 9.32 | 11.46 |
Against major listed peers, the stock looks relatively balanced on earnings valuation but stronger than several names on return ratios. Compared with Apollo Hospitals Enterprise, it trades at a near-identical P/E of 60.09 versus 60.97 and a slightly lower P/B of 12.46 versus 13.15. Apollo’s ROE of 23.54% is marginally higher, but the company’s ROCE of 29.56% is above Apollo’s 21.73%.
Versus Max Healthcare, Fortis Healthcare and Manipal Health, its P/E is lower than all three. Its ROE and ROCE are also stronger than those three peers on the supplied data. Aster DM Healthcare stands out as a much more expensive peer on earnings, with a P/E of 206.73 and P/B of 13.26 despite lower ROE of 9.32% and ROCE of 11.46%.
On market capitalisation, the company at Rs 32,406.57 crore is smaller than Apollo, Manipal, Max, Fortis and Aster in this peer set, but it is close to Krishna Institute of Medical Sciences at Rs 32,332.10 crore in the broader benchmark list. Taken together, the peer data suggests the valuation is not unusual for a premium healthcare name on P/E, though the P/B multiple remains elevated.
Why Investors Are Watching Dr. Lal Pathlabs
- The stock fell 2.51% to Rs 1,891.25 from the previous close of Rs 1,939.95.
- The current price is slightly below the 50-day moving average of Rs 1,894.01, but well above the 200-day moving average of Rs 1,586.05.
- P/E at 60.09 and P/B at 12.46 keep valuation in focus after any price decline.
- ROE of 22.37% and ROCE of 29.56% remain stronger than industry median profitability levels.
- The company operates in a premium-valued Healthcare industry where peer comparisons matter.
About Dr. Lal Pathlabs
Dr. Lal Pathlabs operates within the Healthcare sector and the Hospital & Healthcare Services industry. Based on the supplied classification, it sits in a segment where listed companies often command very different valuation multiples, making comparisons on profitability and scale especially important.
With a market capitalisation of Rs 32,406.57 crore, the company is one of the larger listed names in its industry, though smaller than several hospital-led peers in the supplied comparison set. In market terms, Dr. Lal Pathlabs Share Price is often tracked through sector valuations, return ratios and relative positioning against other healthcare-service businesses.
Track Dr. Lal Pathlabs Share Price on Univest
Use Dr. Lal Pathlabs (LALPATHLAB) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors can use Univest to track live price moves, technical indicators, valuation ratios and broader market context in one place, while also comparing the stock with sector peers through a more structured workflow.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Dr. Lal Pathlabs Share Price falling today?
Ans. Dr. Lal Pathlabs Share Price was down 2.51% at Rs 1,891.25 versus the previous close of Rs 1,939.95. The supplied data confirms the decline, but it does not establish a company-specific catalyst for today’s move.
What is the current Dr. Lal Pathlabs Share Price Today?
Ans. The stock stands at Rs 1,891.25 as of the supplied timestamp. It opened at Rs 1,923.45, touched a high of Rs 1,934.80 and moved to an intraday low of Rs 1,876.
How much did Dr. Lal Pathlabs stock fall today?
Ans. The stock declined by Rs 48.70 in absolute terms and by 2.51% on the day from a previous close of Rs 1,939.95. The previous close was Rs 1,939.95. The stock moved 2.51% lower during the session.
What do the valuation ratios say about Dr. Lal Pathlabs?
Ans. The stock trades at a P/E of 60.09 and a P/B of 12.46. Its P/E is above the industry median of 47.88 but below the industry average of 103.86, while P/B is well above benchmark medians.
How profitable is Dr. Lal Pathlabs compared with its industry?
Ans. Profitability appears strong on the supplied numbers. ROE is 22.37% versus an industry median of 12.82%, while ROCE is 29.56% against a median of 15.7%. The stock belongs to the Healthcare sector.
How does Dr. Lal Pathlabs compare with Apollo Hospitals?
Ans. It trades at a P/E of 60.09 against Apollo Hospitals’ 60.97 and a P/B of 12.46 against 13.15. Its ROCE of 29.56% is higher, while Apollo’s ROE of 23.54% is slightly stronger.
Which sector does Dr. Lal Pathlabs belong to?
Ans. Dr. Lal Pathlabs belongs to the Healthcare sector and the Hospital & Healthcare Services industry. In the supplied same-industry benchmark, the comparison set covers 62 companies. The stock belongs to the Healthcare sector.
